Conditions: Advanced Non-Hematologic Malignancies
Keywords: Neoplasms monoclonal antibody PF-04605412 advanced metastatic solid tumors
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 33
Healthy volunteers: no

Brief summary:
Dose finding study of the MoaB PF-04605412 directed against the alpha5beta1 integrin. Main objective is to define the MTD (maximum tolerated dose) or MAD (maximum administrable dose) in cancer patients pre treated or unresponsive to standard therapies.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: PF-04605412
Intervention descriptions: intervention 1: PF-04605412 will be administered as 2 hr IV infusion every 4 or 2 weeks. Start dose is 7.5 mg. Multiple doses are foreseen. Treatment will continue until intolerable toxicity, progression of disease or patient's refusal

Protocol document: